Huang Jiegang, Yang Shanyin, Xie Zhiman, Guo Baodong, Lan Yingji, Li Yanjun, Jiang Yuan, Forman Leah S, Lunze Karsten, Liang Bingyu, Abdullah Abu S, Ye Li, Liang Hao, Quintiliani Lisa M
School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Medical University, Nanning, Guangxi, China.
AIDS Behav. 2025 Jul 24. doi: 10.1007/s10461-025-04823-7.
Cigarette smoking among people with HIV is a leading preventable cause of morbidity and mortality, particularly in China given its immense burden of smoking. This pilot study aimed to evaluate the feasibility, acceptability, and efficacy on smoking cessation of a community-informed WeChat-based messaging and behavioral counseling intervention for people with HIV who smoke called Quit for Life. The study design was a 2-group randomized clinical trial. Data collection occurred between February 2022 and August 2023 within a tertiary infectious disease hospital in Nanning city, Guangxi, China. Participants included adults with HIV who smoked, were willing to set a quit date, and received HIV care at the hospital. Participants were randomized to the 8-week Quit for Life intervention group (nicotine replacement therapy gum, self-help quitting smoking guide, behavioral counseling, and WeChat-based messaging), or the control group (nicotine replacement therapy gum and self-help guide only). Complete case analysis was performed. Of 219 people assessed for eligibility, 109 participants were randomized (mean [SD] age, 45.3 [15.1] years; men [96.3%]) and 98 completed the 12-week assessment (89.9% retention rate). At 12-week follow-up, the biochemically verified smoking cessation rate (primary outcome) was significantly higher in the intervention group compared to the control group (59.1% abstinence vs. 25.6%, adjusted odds ratio 5.3 [1.5,19.2]. Implementation and feasibility metrics indicated most participants receiving the intervention as intended gave high ratings of the usefulness of counseling sessions and WeChat-based messaging. Given these findings, subsequent studies should investigate implementation and scale-up of this intervention for people with HIV in China.Clinical trial registration details: Trial registration number: ClinicalTrials.gov Identifier: NCT05020899. Date of trial registration: 8-19-2021.
在艾滋病毒感染者中，吸烟是导致发病和死亡的主要可预防原因，在中国尤其如此，因为中国吸烟负担极为沉重。这项试点研究旨在评估一种名为“为生命戒烟”的、基于微信的信息推送与行为咨询干预措施对吸烟的艾滋病毒感染者戒烟的可行性、可接受性和有效性。该研究设计为两组随机临床试验。数据收集于2022年2月至2023年8月在中国广西南宁市的一家三级传染病医院内进行。参与者包括吸烟的成年艾滋病毒感染者，他们愿意设定戒烟日期，并在该医院接受艾滋病毒护理。参与者被随机分为8周的“为生命戒烟”干预组（尼古丁替代疗法口香糖、自助戒烟指南、行为咨询以及基于微信的信息推送）或对照组（仅尼古丁替代疗法口香糖和自助指南）。进行了完全病例分析。在219名评估合格的人中，109名参与者被随机分组（平均[标准差]年龄为45.3[15.1]岁；男性占[96.3%]），98人完成了12周评估（保留率为89.9%）。在12周随访时，干预组经生化验证的戒烟率（主要结局）显著高于对照组（戒断率为59.1%对25.6%，调整后的优势比为5.3[1.5,19.2]）。实施情况和可行性指标表明，大多数按预期接受干预的参与者对咨询会议和基于微信的信息推送的有用性给予了高度评价。鉴于这些发现，后续研究应调查在中国对艾滋病毒感染者实施该干预措施并扩大规模的情况。临床试验注册详情：试验注册号：ClinicalTrials.gov标识符：NCT05020899。试验注册日期：2021年8月19日。
